Actuate Therapeutics Inc (ACTU)

Apr 29, 2026

Actuate Therapeutics (ACTU) price target decreased by 17.00% to 21.16 - MSN

Apr 29, 2026

Apr 28, 2026

Short Interest in Actuate Therapeutics, Inc. (NASDAQ:ACTU) Grows By 40.1% - MarketBeat

Apr 28, 2026

Apr 27, 2026

Actuate Therapeutics announces public offering of common stock - MSN

Apr 27, 2026

Apr 22, 2026

Why did Actuate Therapeutics (ACTU) stock jump over 14% after hours? - MSN

Apr 22, 2026

Apr 22, 2026

Actuate Therapeutics drug improves survival odds in pancreatic cancer trial - whbl.com

Apr 22, 2026

Apr 22, 2026

H.C. Wainwright Maintains Actuate Therapeutics(ACTU.US) With Buy Rating, Maintains Target Price $15 - Moomoo

Apr 22, 2026

Apr 22, 2026

HC Wainwright Reiterates "Buy" Rating for Actuate Therapeutics (NASDAQ:ACTU) - MarketBeat

Apr 22, 2026

Apr 22, 2026

H.C. Wainwright reiterates Buy on Actuate Therapeutics stock By Investing.com - Investing.com Canada

Apr 22, 2026

Apr 22, 2026

Actuate Therapeutics Inc - Reuters

Apr 22, 2026

Apr 21, 2026

12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga

Apr 21, 2026

Apr 21, 2026

Health Rounds: Actuate Therapeutics drug improves survival odds in pancreatic cancer trial - TradingView

Apr 21, 2026

Apr 17, 2026

12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga

Apr 17, 2026

Apr 17, 2026

Why Did Actuate Therapeutics (ACTU) Stock Jump Over 14% After Hours? - Sahm

Apr 17, 2026

Apr 15, 2026

12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga

Apr 15, 2026

Apr 15, 2026

HC Wainwright Issues Optimistic Estimate for ACTU Earnings - National Today

Apr 15, 2026

Apr 15, 2026

B.Riley cuts Actuate Therapeutics stock price target on revenue timing - Investing.com

Apr 15, 2026

Apr 14, 2026

Actuate Therapeutics Reports Significant Survival Improvement in Phase 2 Trial of Elraglusib for Metastatic Pancreatic Cancer - Quiver Quantitative

Apr 14, 2026

Apr 14, 2026

Pancreatic cancer trial doubled one-year survival in study - Stock Titan

Apr 14, 2026

Apr 14, 2026

Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma - GlobeNewswire

Apr 14, 2026

Apr 14, 2026

Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial - Nature

Apr 14, 2026

Apr 13, 2026

ACTU Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus

Apr 13, 2026

Apr 13, 2026

H.C. Wainwright Maintains Actuate Therapeutics(ACTU.US) With Buy Rating, Cuts Target Price to $15 - Moomoo

Apr 13, 2026

Apr 13, 2026

Netflix To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga

Apr 13, 2026

Apr 13, 2026

H.C. Wainwright lowers Actuate Therapeutics price target on strategy shift By Investing.com - Investing.com Canada

Apr 13, 2026

Apr 13, 2026

H.C. Wainwright lowers Actuate Therapeutics price target on strategy shift - Investing.com

Apr 13, 2026

Apr 09, 2026

Activity Recap: Can Actuate Therapeutics Inc scale operations efficiently2026 Price Action Summary & Weekly Stock Breakout Alerts - baoquankhu1.vn

Apr 09, 2026

Apr 09, 2026

Published on: 2026-04-09 23:48:44 - baoquankhu1.vn

Apr 09, 2026

Apr 09, 2026

Aug Levels: Does Actuate Therapeutics Inc have consistent dividend growth2026 Intraday Action & Community Consensus Trade Signals - baoquankhu1.vn

Apr 09, 2026

Apr 09, 2026

Actuate Therapeutics | ARS: Annual Report to Security Holders - Moomoo

Apr 09, 2026

Apr 06, 2026

Profit Review: Is Actuate Therapeutics Inc benefiting from innovation trendsWeekly Trade Analysis & Consistent Return Strategy Ideas - baoquankhu1.vn

Apr 06, 2026

Apr 06, 2026

Will Actuate (ACTU) Stock Beat Expectations | Price at $2.10, Down 15.32%Community Buy Signals - Newser

Apr 06, 2026

Apr 04, 2026

Actuate Therapeutics (NASDAQ:ACTU) Raised to Hold at Wall Street Zen - MarketBeat

Apr 04, 2026

Apr 01, 2026

ACTU Technical Analysis & Stock Price Forecast - Intellectia AI

Apr 01, 2026

Apr 01, 2026

Actuate Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Mazar Andrew Paul - Moomoo

Apr 01, 2026

Mar 27, 2026

Aug Setups: Is Actuate Therapeutics Inc stock showing strong momentum2026 Short Interest & Accurate Intraday Trading Signals - baoquankhu1.vn

Mar 27, 2026

Mar 26, 2026

Actuate Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener

Mar 26, 2026

Mar 25, 2026

Actuate Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com

Mar 25, 2026

Mar 24, 2026

Actuate Therapeutics: Poised for Potential $200M+ Pediatric Priority Review Vouchers and Transformative Combinations in RAS-Driven Cancers - Finviz

Mar 24, 2026

Mar 22, 2026

Aug Levels: Is Actuate Therapeutics Inc benefiting from innovation trends2026 Retail & Safe Entry Point Identification - baoquankhu1.vn

Mar 22, 2026

Mar 21, 2026

Aug Outlook: Can Actuate Therapeutics Inc scale operations efficiently2026 Selloffs & Entry Point Confirmation Signals - baoquankhu1.vn

Mar 21, 2026

Mar 20, 2026

Actuate Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | ACTU | US0050831009 - marketscreener.com

Mar 20, 2026

Mar 18, 2026

Aug Shorts: Can Actuate Therapeutics Inc outperform under higher oil pricesWeekly Trade Summary & Reliable Momentum Entry Alerts - baoquankhu1.vn

Mar 18, 2026

Mar 18, 2026

Voss Capital LP Boosts Stake in Actuate Therapeutics, Inc. $ACTU - MarketBeat

Mar 18, 2026

Mar 14, 2026

How Much Upside is Left in Actuate Therapeutics, Inc. (ACTU)? Wall Street Analysts Think 214.06% - MSN

Mar 14, 2026

Mar 11, 2026

Actuate Therapeutics Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView

Mar 11, 2026

Mar 09, 2026

Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors - Bitget

Mar 09, 2026